Skip to content
★ Sign in to follow
SM

Sisram Medical Ltd. Stock: price and insider trades · Hong Kong

HK·Mcap HK$852.3M

No insider purchase over the last 90 days. The latest, by Liu Yi, was filed 22 Dec 2021.

Sisram Medical Ltd.: what insiders have been doing

Every trade that managers of Sisram Medical Ltd. disclose to HKEX is tracked on this page. In the past year (20 October 2025 to 20 October 2026), 2 filings came from 2 insiders.

No insider bought on the market over the period, while 2 insiders filed 2 sales. The totals exclude 2 filings filed without an amount.

Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

For context, the typical company on the same exchange (median of 1,318 companies) published 4 filings over the same period, against 2 filings here. The full history, which starts in 2017, counts 7 purchases against 4 sales.

In the same market, recent insider purchases at Sun Hung Kai Properties Ltd. and Xinyi Glass Holdings Ltd. also feature in our signals. These figures are compiled from regulatory filings published by HKEX. They describe what insiders did and are not a recommendation.

Insider Decl.
13
Thresholds
n/a
Buy Volume
€120,780
7 ops. · all time
Sell Volume
n/a
4 ops. · all time

Who traded when

BuySale
Dayan Lior Moshe2 sales
Liu Yi2 sales

Since the insiders bought

  • Filed 22 Dec 2021 · 1782 days ago · €30k
    -20.5%
    Entry HK$9.42 · Close at T+365 HK$7.49
  • Filed 08 Oct 2021 · 1857 days ago · €31k
    -54.6%
    Entry HK$12.96 · Close at T+365 HK$5.89

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Analyst consensus: bullish or bearish?

Analysts rate Sisram Medical Ltd. Strong Buy (bullish), based on 2 analysts. Average price target: HK$4.41.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 14,819 of 26,897 companies
48.5
score / 100
Value
38
Quality
59
FCF yld0.8%
Earn yld2.2%
EV/EBITDA18.4x
ROE3.5%
Gross mgn59%
Net mgn5.2%
Debt/EBITDA1.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

HK$1.82
Analyst consensus
2 analysts
Strong buy
HK$4.31Target HK$4.41(+142%)HK$4.51
Income statement
RevenueHK$365.3M
Gross profitHK$215.1M59% margin
EBITDAHK$49.1M13% margin
Net incomeHK$19M3.1% margin
Valuation
PER (trailing)7.9x
PER (forward)21.3x
P/Book0.2x
Beta0.62
Balance sheet & cash
Market capHK$852.3M
Total debtHK$51.8M
Free Cash FlowHK$6.8M
Debt / Equity16%
Profitability & ownership
ROE3.5%
ROA2.0%
% insiders71.6%
% institutions0.3%
Last declaration on 2 December 2025
Declarations13 total
  • ▼
    DirectorExecutives
    0HKEX
    200,000 sharesShareXHKGHKEX:DA20251202E00182
  • ▼
    DirectorExecutives
    0HKEX
    55,000 sharesShareXHKGHKEX:DA20251202E00184
  • ▼
    DirectorExecutives
    0HKEX
    200,000 sharesShareXHKGHKEX:DA20241203E00298
  • ▼
    DirectorExecutives
    0HKEX
    55,000 sharesShareXHKGHKEX:DA20241203E00311
  • ●
    DirectorExecutives
    0HKEX
    200,000 sharesShareXHKGHKEX:DA20240110E00562
  • ●
    DirectorExecutives
    0HKEX
    55,000 sharesShareXHKGHKEX:DA20240110E00560
  • ▲
    DirectorExecutives
    266,730 HKD19HKEX
    30,000 shares@ HK$8.891100.0% of flowShareXHKGHKEX:DA20211222E00187
    Canonical exit: 21 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    80,000 shares0ShareXHKGHKEX:DA20211207E00029
    Canonical exit: 2 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    220,000 shares0ShareXHKGHKEX:DA20211207E00030
    Canonical exit: 2 Mar 2022 (T+90)
  • ▲
    DirectorExecutives
    0HKEX
    800,000 shares0ShareXHKGHKEX:DA20211203E00132
    Canonical exit: 28 Feb 2022 (T+90)
  • ▲
    DirectorExecutives
    276,125 HKD14HKEX
    25,000 shares@ HK$11.04533.9% of flowShareXHKGHKEX:DA20211008E00134
    Canonical exit: 4 Jan 2022 (T+90)
  • ▲
    DirectorExecutives
    308,373 HKD15HKEX
    77,500 shares@ HK$3.97938.7% of flowShareXHKGHKEX:DA20190716E00410
    Canonical exit: 9 Oct 2019 (T+90)
  • ▲
    DirectorExecutives
    226,800 HKD14HKEX
    36,000 shares@ HK$6.3027.3% of flowShareXHKGHKEX:DA20171124E00200
    Canonical exit: 20 Feb 2018 (T+90)

13 of 13 declarations

About Sisram Medical Ltd.

Sisram Medical Ltd. is a company focused on the development and commercialization of medical technologies, particularly in the aesthetic field. It is listed on the Hong Kong Stock Exchange.

Recent ranked signals on the same market

Purchases our model currently ranks for the recommendations list.

All recommendations